Review
Cell Biology
Edward P. Carter, Abigail S. Coetzee, Elena Tomas Bort, Qiaoying Wang, Hemant M. Kocher, Richard P. Grose
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to challenges in treatment and late detection, with the FGFR signalling pathway playing a critical role in tumor progression and interaction with the tumor microenvironment. However, it is clear that the FGFR signalling pathway does not act in isolation and interacts with other signaling networks. Therapeutic approaches are being developed to improve prognosis for this terrible disease.
Editorial Material
Biochemistry & Molecular Biology
Duarte Mateus, Antoni Wiedlocha
Summary: This study investigates the role of the fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling axis in the development of invasive cervical cancer and highlights its importance as an additional factor for the development of highly malignant tumors.
Review
Oncology
Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, Lukasz Opalinski, Jacek Otlewski, Malgorzata Zakrzewska
Summary: Deregulation of the FGF/FGFR axis in cancer contributes to the development of chemoresistance, limiting the effectiveness of current treatment strategies. This dysfunction generates molecular mechanisms that may affect tumor sensitivity to drugs by promoting cell proliferation, survival, motility, and inhibiting apoptosis. Targeting components of the FGFR/FGF signaling module appears to be a promising approach to overcome drug resistance in cancer therapy, despite the potential for further resistance development through specific mutations and molecular cross-talks.
Review
Biochemistry & Molecular Biology
Subhasmita Mahapatra, Nisha Amarnath Jonniya, Suman Koirala, Kapil Dattatray Ursal, Parimal Kar
Summary: Fibroblast Growth Factor (FGF) ligands and their receptors, FGFR, play a crucial role in chemoresistance in several malignancies. Dysfunction of FGF/FGFR signaling pathways in tumor cells affects drug effectiveness. Overexpression and mutation of FGF/FGFR induce regulatory changes in signaling pathways, leading to drug resistance. Inhibition of FGF/FGFR through various therapeutic approaches may provide solutions to this problem.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Oncology
Yijun Wang, Danfei Liu, Tongyue Zhang, Limin Xia
Summary: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, ranking third in cancer deaths worldwide. Studies have focused on developing tyrosine kinase inhibitors (TKIs) to target aberrant pathways in HCC, but outcomes are unsatisfactory due to resistance and adverse effects. The fibroblast growth factor (FGF) family and its receptors (FGFR) play crucial roles in various biological processes and are also implicated in HCC. Anti-FGF/FGFR therapies show promising benefits for cancer patients with FGF signaling alterations, and new multi-kinase inhibitors targeting FGF signaling are under investigation for HCC treatment.
Article
Genetics & Heredity
Qiuxiang Chen, Xiaojing Du
Summary: FGF/FGFR-related lncRNAs play important roles in gastric cancer and can serve as biomarkers for prognosis and treatment response. A risk score model incorporating four lncRNAs can predict the prognosis of gastric cancer. Patients can be divided into different groups based on the risk score, showing distinct tumor features and treatment sensitivity. Additionally, specific drugs may be sensitive to the high-risk score group.
FRONTIERS IN GENETICS
(2022)
Review
Medicine, General & Internal
Jin-Shou Yang, Cheng-Cheng Wang, Jiang-Dong Qiu, Bo Ren, Lei You
Summary: PDAC is an extremely malignant disease with a low survival rate, with arginine metabolism playing a crucial role in its development and progression. Arginine deprivation is considered a potential therapy, but drug resistance may develop during treatment. Arginase 1 may be a potential target for cancer immunotherapy.
CHINESE MEDICAL JOURNAL
(2021)
Article
Biology
Csongor G. Lengyel, Sadaqat Hussain, Andreas Seeber, Sara Jamil Nidhamalddin, Dario Trapani, Baker S. Habeeb, Essam Elfaham, Syed Ayub Mazher, Fahmi Seid, Shah Z. Khan, Khalid El Bairi, Andrew Odhiambo, Sara C. Altuna, Angelica Petrillo
Summary: Gastric cancer is the third leading cause of cancer-related death worldwide. Late diagnosis and lack of screening programs are major challenges. Novel diagnostic techniques and molecular pathways, such as the FGFR pathway, have been identified to improve survival in gastric cancer patients.
Article
Biotechnology & Applied Microbiology
Xiaomei Zhang, Huifeng Zhang, Jingli Gong, Huan Yu, Di Wu, Junyu Hou, Minghui Li, Xin Sun
Summary: This study evaluated the anti-aging effect of uridine in a senescent gastric epithelial cell model and found that uridine could decrease the aging level, reduce inflammation and oxidative stress, and restore the sensitivity of FGF signaling. This research lays a solid foundation for further studies in this field.
Article
Biochemistry & Molecular Biology
Alessandra Loda, Marta Turati, Francesco Semeraro, Sara Rezzola, Roberto Ronca
Summary: Ocular tumors are rare neoplasms that develop in the eye. Current treatments can control the local tumor, but some patients develop metastatic disease. New targets and players are needed to prevent and control tumor growth and metastasis. The fibroblast growth factor/receptor system plays a relevant role in ocular tumors and may have prognostic and therapeutic implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biology
Jorge A. Roacho-Perez, Elsa N. Garza-Trevino, Paulina Delgado-Gonzalez, Zuca G-Buentello, Juan Luis Delgado-Gallegos, Christian Chapa-Gonzalez, Margarita Sanchez-Dominguez, Celia N. Sanchez-Dominguez, Jose Francisco Islas
Summary: Pancreatic cancer is the most common lethal tumor in America, with limited treatment options and several side effects. Utilizing targeted nanoparticles as an alternative treatment for pancreatic cancer aims to reduce side effects and improve treatment outcomes by identifying and attacking cancer cells specifically.
Review
Oncology
Zechen Wang, Karen S. Anderson
Summary: Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most prevalent cancer worldwide, with a stagnant overall survival rate. Genomic alterations of fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) are common in HNSCC, and preclinical studies demonstrate the potential of FGFR inhibitors in combination treatment regimens.
Review
Oncology
Jin-Fen Xiao, Andrew W. Caliri, Jason E. Duex, Dan Theodorescu
Summary: This review discusses the presence of unfavorable genetic alterations in the FGFR3 gene in 20% of advanced bladder cancer patients and explores the potential therapeutic strategies targeting these alterations and mechanisms of drug resistance. It also highlights the clinical findings of combining FGFR inhibition with other targeted inhibitors and/or immunotherapy to improve outcomes for patients with suboptimal responses to FGFR3-directed monotherapy.
Article
Biochemistry & Molecular Biology
Rana Smalling, Matthew E. Bechard, Jeff Duryea, Philip J. Kingsley, Evan R. Roberts, Lawrence J. Marnett, Daniel Bilbao, Shaun R. Stauffer, Oliver G. McDonald
Summary: A novel aminopyridine compound was found to target a unique metabolic adaptation in metastatic pancreatic cancer, demonstrating effective anti-metastatic efficacy with minimal toxicity. This discovery could potentially provide new druggable targets for patients with advanced cancers.
Article
Multidisciplinary Sciences
Wenxin Qi, Qian Liu, Wenjun Fu, Jiaming Shi, Minmin Shi, Songqi Duan, Zhe Li, Shaohua Song, Jiao Wang, Yihao Liu
Summary: This study found that BHLHE40 is highly expressed in pancreatic cancer tissues and is associated with poor prognosis of patients. Further experiments revealed that BHLHE40 may be involved in immunosuppression of pancreatic cancer. Silencing BHLHE40 can inhibit the proliferation, invasion, and apoptosis of pancreatic cancer cells, suggesting that BHLHE40 is a potential therapeutic target for pancreatic cancer.
SCIENTIFIC REPORTS
(2023)
